Upstream Bio, Inc. Overview
Pro stress-test →Upstream Bio is a clinical-stage biotechnology company developing treatments for inflammatory diseases focusing on severe respiratory disorders, with its lead candidate verekitug in Phase 2 clinical development for severe asthma and chronic rhinosinusitis with nasal polyps, and in Phase 1 trials for COPD. The company recently achieved a critical milestone with positive Phase 2 trial data in February 2026.
Strategic Profile
Pro stress-test →Verekitug is the only known antagonist currently in development that targets the receptor for thymic stromal lymphopoietin (TSLP), a cytokine positioned upstream of multiple signaling cascades affecting various immune-mediated diseases. This novel mechanism of action addresses significant unmet needs in respiratory inflammation treatment with potential applications beyond the initial respiratory disease focus.
Competitive Landscape
Pro stress-test →Upstream Bio competes in the severe respiratory inflammation space against established therapies and newer biologics from larger pharma. The company's differentiated TSLP antagonism mechanism provides competitive advantages versus current standard-of-care asthma treatments and other emerging respiratory therapeutics, though success depends on Phase 2/3 trial progression.
Industry Context
Upstream Bio, Inc. operates in Pharmaceutical Biotechnology - Respiratory/Inflammatory Diseases.
Key facts
Founded: 2021 · Headquarters: Waltham, Massachusetts · Market cap: $1.68B